When putting together your watch list, focus on stocks with an 80 or higher RS Rating. LENZ Therapeutics now meets that criteria, with a jump from 79 to 85 Friday.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
History reveals that the market's biggest winners typically have an RS Rating north of 80 as they launch their biggest climbs.
LENZ Therapeutics is now considered extended and out of buy range after clearing a 25.77 buy point in a second-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
The company reported 0% EPS growth in the latest quarterly report. Sales rose 0%.
LENZ Therapeutics earns the No. 157 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Rigel Pharmaceuticals and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
